Targets › TRPV1
11 programs from 9 companies in 16 trials: 7 Phase 2, 4 Phase 3, 3 Phase 4, 2 Phase 1; Neurology, Other, Psychiatry; next expected readout Dec 2026.
Non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. (UniProt, Q8NER1)
Open in Phaseline: the race on TRPV1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospital, Clermont-Ferrand | Capsaicin Vanilloid receptor opener | TRPV1 | Phase 4 | Osteoarthritis Hand | Jan 2028 |
| Heron Therapeutics | HTX-011 Fixed-ratio combination of bupivacaine and meloxicam; bupivacaine is a local anesthetic th | TRPV1 | Phase 4 | Analgesia | – |
| Valenta Pharm JSC | 4-MUST (trimebutine 4-methylumbelliferyl sulfate) Trimebutine derivative; prokinetic agent acting as TRPV1 agonist and 5-HT4 receptor agonis | TRPV1, HTR4 | Phase 3 | Chronic Cholecystitis | Dec 2026 |
| Nantes University Hospital | Capsaicin Vanilloid receptor opener | TRPV1 | Phase 3 | Coccyx Disorder | May 2027 |
| Institut Cancerologie de l'Ouest | Capsaicin Vanilloid receptor opener | TRPV1 | Phase 3 | Chemotherapy-induced Peripheral Neuropathy | Mar 2028 |
| University Hospital, Brest | Capsaicin Vanilloid receptor opener | TRPV1 | Phase 3 | Neuropathic Pain | Jul 2028 |
| RDC Clinical | Oleoylethanolamide (Trpti) Endocannabinoid-like compound; TRPV1 and PPAR-alpha agonist with appetite regulation and s | TRPV1, PPARA | Phase 2 | Sleep Disorder (Disorder); Healthy Volunteers | Feb 2027 |
| RDC Clinical | Palmitoylethanolamide (PEA) Endocannabinoid-like lipid signaling molecule; acts as agonist at TRPV1 and PPARα receptor | TRPV1, PPARA | Phase 2 | Sleep Disorder (Disorder); Healthy; Persistent Postural Perceptual Dizziness | Feb 2027 |
| Instituto Mexicano del Seguro Social | Capsaicin Vanilloid receptor opener | TRPV1 | Phase 2 | Ischemic Stroke | – |
| RDC Clinical | Levagen+ (palmitoylethanolamide, PEA) Lipid signaling molecule; TRPV1 antagonist and PPARδ agonist with anti-inflammatory and ne | TRPV1, PPARD | Phase 2 | Diabetic Peripheral Neuropathy | – |
| Universiti Kebangsaan Malaysia Medical Centre | Lignocaine-loaded maltose microneedle array patch Local anesthetic delivered via biodegradable maltose microneedle array for enhanced transd | TRPV1 | Phase 1 | Glaucoma | Dec 2026 |
Chronic Cholecystitis (3) Sleep Disorder (Disorder) (2) Neuropathic Pain (1) Chemotherapy-induced Peripheral Neuropathy (1) Glaucoma (1) Osteoarthritis Hand (1) Coccyx Disorder (1) Analgesia (1) Ischemic Stroke (1) Healthy (1) Persistent Postural Perceptual Dizziness (1) Healthy Volunteers (1)
small molecule (8)
RDC Clinical (3) University Hospital, Brest (1) Institut Cancerologie de l'Ouest (1) Universiti Kebangsaan Malaysia Medical Centre (1) University Hospital, Clermont-Ferrand (1) Nantes University Hospital (1) Valenta Pharm JSC (1) Heron Therapeutics (1) Instituto Mexicano del Seguro Social (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.